The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Indivumed; Ipsen; MSD Oncology
Speakers' Bureau - Eisai; Eisai; Lilly
Research Funding - ASLAN Pharmaceuticals; Bayer; Bristol-Myers Squibb; Eisai; Immunomet; medpacto; MSD Oncology; Roche/Genentech; Sillajen
 
Chang Gon Kim
No Relationships to Disclose
 
Minkyu Jung
No Relationships to Disclose
 
Hyo Song Kim
No Relationships to Disclose
 
Choong-kun Lee
No Relationships to Disclose
 
Hei-Cheul Jeung
No Relationships to Disclose
 
Dong-Hoe Koo
No Relationships to Disclose
 
Woo Kyun Bae
No Relationships to Disclose
 
Dae Young Zang
No Relationships to Disclose
 
Hyunki Kim
No Relationships to Disclose
 
Hyun Cheol Cheol Chung
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Amgen (Inst); Beigene (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)